In vitro activity of gemifloxacin against recent clinical isolates of bacteria in Korea.

DongEun Yong, Hee Jin Cheong, Yang Soo Kim, Yeon Joon Park, Woo Joo Kim, Jun Hee Woo, Kyungwon Lee, Moon Won Kang, Youn Sung Choo

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Gemifloxacin is an enhanced-affinity fluoroquinolone with broad-spectrum antibacterial activity. In Korea, resistant bacteria are relatively more prevalent than in other industrialized countries. In this study, we studied the in vitro activities of gemifloxacin, gatifloxacin, moxifloxacin, levofloxacin, ciprofloxacin, and other commonly used antimicrobial agents against 1,689 bacterial strains isolated at four Korean university hospitals during 1999-2000. Minimum inhibitory concentrations (MICs) were determined using the agar dilution method of National Committee for Clinical Laboratory Standards. Gemifloxacin had the lowest MICs for the respiratory pathogens: 90% of Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae were inhibited by 0.06, 0.03, and 0.03 mg/L, respectively. Gemifloxacin was more active than the other fluoroquinolones against methicillin-susceptible Staphylococcus aureus, coagulase-negative staphylococci, streptococci, and Enterococcus faecalis. The MIC90s of gemifloxacin for Klebsiella oxytoca, Proteus vulgaris, and non-typhoidal Salmonella spp. were 0.25, 1.0, and 0.12 mg/L, respectively, while those for other Gram-negative bacilli were 4-64 mg/L. In conclusion, gemifloxacin was the most active among the comparative agents against Gram-positive species, including respiratory pathogens isolated in Korea.

Original languageEnglish
Pages (from-to)737-742
Number of pages6
JournalJournal of Korean medical science
Volume17
Issue number6
DOIs
Publication statusPublished - 2002 Jan 1

Fingerprint

Korea
Bacteria
Enterococcus faecalis
Fluoroquinolones
Microbial Sensitivity Tests
Klebsiella oxytoca
Proteus vulgaris
Moraxella (Branhamella) catarrhalis
Levofloxacin
Methicillin
Coagulase
Haemophilus influenzae
Ciprofloxacin
Anti-Infective Agents
Streptococcus pneumoniae
Staphylococcus
Developed Countries
Salmonella
Bacillus
Agar

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Yong, DongEun ; Cheong, Hee Jin ; Kim, Yang Soo ; Park, Yeon Joon ; Kim, Woo Joo ; Woo, Jun Hee ; Lee, Kyungwon ; Kang, Moon Won ; Choo, Youn Sung. / In vitro activity of gemifloxacin against recent clinical isolates of bacteria in Korea. In: Journal of Korean medical science. 2002 ; Vol. 17, No. 6. pp. 737-742.
@article{96c6f9438fbf4224a71ed9f0bc6a0b6e,
title = "In vitro activity of gemifloxacin against recent clinical isolates of bacteria in Korea.",
abstract = "Gemifloxacin is an enhanced-affinity fluoroquinolone with broad-spectrum antibacterial activity. In Korea, resistant bacteria are relatively more prevalent than in other industrialized countries. In this study, we studied the in vitro activities of gemifloxacin, gatifloxacin, moxifloxacin, levofloxacin, ciprofloxacin, and other commonly used antimicrobial agents against 1,689 bacterial strains isolated at four Korean university hospitals during 1999-2000. Minimum inhibitory concentrations (MICs) were determined using the agar dilution method of National Committee for Clinical Laboratory Standards. Gemifloxacin had the lowest MICs for the respiratory pathogens: 90{\%} of Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae were inhibited by 0.06, 0.03, and 0.03 mg/L, respectively. Gemifloxacin was more active than the other fluoroquinolones against methicillin-susceptible Staphylococcus aureus, coagulase-negative staphylococci, streptococci, and Enterococcus faecalis. The MIC90s of gemifloxacin for Klebsiella oxytoca, Proteus vulgaris, and non-typhoidal Salmonella spp. were 0.25, 1.0, and 0.12 mg/L, respectively, while those for other Gram-negative bacilli were 4-64 mg/L. In conclusion, gemifloxacin was the most active among the comparative agents against Gram-positive species, including respiratory pathogens isolated in Korea.",
author = "DongEun Yong and Cheong, {Hee Jin} and Kim, {Yang Soo} and Park, {Yeon Joon} and Kim, {Woo Joo} and Woo, {Jun Hee} and Kyungwon Lee and Kang, {Moon Won} and Choo, {Youn Sung}",
year = "2002",
month = "1",
day = "1",
doi = "10.3346/jkms.2002.17.6.737",
language = "English",
volume = "17",
pages = "737--742",
journal = "Journal of Korean Medical Science",
issn = "1011-8934",
publisher = "Korean Academy of Medical Science",
number = "6",

}

In vitro activity of gemifloxacin against recent clinical isolates of bacteria in Korea. / Yong, DongEun; Cheong, Hee Jin; Kim, Yang Soo; Park, Yeon Joon; Kim, Woo Joo; Woo, Jun Hee; Lee, Kyungwon; Kang, Moon Won; Choo, Youn Sung.

In: Journal of Korean medical science, Vol. 17, No. 6, 01.01.2002, p. 737-742.

Research output: Contribution to journalArticle

TY - JOUR

T1 - In vitro activity of gemifloxacin against recent clinical isolates of bacteria in Korea.

AU - Yong, DongEun

AU - Cheong, Hee Jin

AU - Kim, Yang Soo

AU - Park, Yeon Joon

AU - Kim, Woo Joo

AU - Woo, Jun Hee

AU - Lee, Kyungwon

AU - Kang, Moon Won

AU - Choo, Youn Sung

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Gemifloxacin is an enhanced-affinity fluoroquinolone with broad-spectrum antibacterial activity. In Korea, resistant bacteria are relatively more prevalent than in other industrialized countries. In this study, we studied the in vitro activities of gemifloxacin, gatifloxacin, moxifloxacin, levofloxacin, ciprofloxacin, and other commonly used antimicrobial agents against 1,689 bacterial strains isolated at four Korean university hospitals during 1999-2000. Minimum inhibitory concentrations (MICs) were determined using the agar dilution method of National Committee for Clinical Laboratory Standards. Gemifloxacin had the lowest MICs for the respiratory pathogens: 90% of Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae were inhibited by 0.06, 0.03, and 0.03 mg/L, respectively. Gemifloxacin was more active than the other fluoroquinolones against methicillin-susceptible Staphylococcus aureus, coagulase-negative staphylococci, streptococci, and Enterococcus faecalis. The MIC90s of gemifloxacin for Klebsiella oxytoca, Proteus vulgaris, and non-typhoidal Salmonella spp. were 0.25, 1.0, and 0.12 mg/L, respectively, while those for other Gram-negative bacilli were 4-64 mg/L. In conclusion, gemifloxacin was the most active among the comparative agents against Gram-positive species, including respiratory pathogens isolated in Korea.

AB - Gemifloxacin is an enhanced-affinity fluoroquinolone with broad-spectrum antibacterial activity. In Korea, resistant bacteria are relatively more prevalent than in other industrialized countries. In this study, we studied the in vitro activities of gemifloxacin, gatifloxacin, moxifloxacin, levofloxacin, ciprofloxacin, and other commonly used antimicrobial agents against 1,689 bacterial strains isolated at four Korean university hospitals during 1999-2000. Minimum inhibitory concentrations (MICs) were determined using the agar dilution method of National Committee for Clinical Laboratory Standards. Gemifloxacin had the lowest MICs for the respiratory pathogens: 90% of Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae were inhibited by 0.06, 0.03, and 0.03 mg/L, respectively. Gemifloxacin was more active than the other fluoroquinolones against methicillin-susceptible Staphylococcus aureus, coagulase-negative staphylococci, streptococci, and Enterococcus faecalis. The MIC90s of gemifloxacin for Klebsiella oxytoca, Proteus vulgaris, and non-typhoidal Salmonella spp. were 0.25, 1.0, and 0.12 mg/L, respectively, while those for other Gram-negative bacilli were 4-64 mg/L. In conclusion, gemifloxacin was the most active among the comparative agents against Gram-positive species, including respiratory pathogens isolated in Korea.

UR - http://www.scopus.com/inward/record.url?scp=0346018968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0346018968&partnerID=8YFLogxK

U2 - 10.3346/jkms.2002.17.6.737

DO - 10.3346/jkms.2002.17.6.737

M3 - Article

VL - 17

SP - 737

EP - 742

JO - Journal of Korean Medical Science

JF - Journal of Korean Medical Science

SN - 1011-8934

IS - 6

ER -